With billions riding on their success, GSK bags quick OK for its two-drug HIV combo Juluca
It cost $130 million, but GSK’s ViiV carved a short path to an FDA approval of its two-drug HIV combo, widely tapped for blockbuster status as Gilead winds up for a likely OK of its rival triple therapy in February.
GSK has been a leader in HIV research, with Gilead, where the focus has been on looking for the simplest approach to safely keeping HIV under medical lock and key in the patient as researchers search for a new way to root it out of cells altogether. Regulators clearly like the way this two-drug, fixed dose combination of dolutegravir and rilpivirine (from J&J) can work on patients’ behalf, replacing other cocktails that require three or more drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.